Zhejiang Taimei Medical Technology Co (FRA:A2V) ROCE %: -3.40% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:A2V Zhejiang Taimei Medical Technology Co Ltd FRA:A2V
11 GF Score
Price €0.60
! 4 Warning Signs
View Full Analysis

What is Zhejiang Taimei Medical Technology Co ROCE %?

Zhejiang Taimei Medical Technology Co FRA:A2V +1.69% 11 ROCE % is -3.40% as of Dec. 2025. GuruFocus rates FRA:A2V with a GF Score™ of 11/100. The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Zhejiang Taimei Medical Technology Co's annualized ROCE % for the quarter that ended in Dec. 2025 was -3.40%.

Zhejiang Taimei Medical Technology Co  (FRA:A2V) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Zhejiang Taimei Medical Technology Co ROCE % Related Terms

Zhejiang Taimei Medical Technology Co ROCE % Historical Data

* Premium members only.

The historical data trend for Zhejiang Taimei Medical Technology Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhejiang Taimei Medical Technology Co ROCE % Chart

Zhejiang Taimei Medical Technology Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
-32.77 -28.69 -27.32 -18.40 -3.80

Zhejiang Taimei Medical Technology Co Semi-Annual Data
Dec21 Dec22 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial 0.00 -32.12 -6.45 -4.31 -3.40
FRA:A2V
11GF Score
Zhejiang Taimei Medical Technology Co Ltd FRA:A2V
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zhejiang Taimei Medical Technology Co ROCE % Calculation

Zhejiang Taimei Medical Technology Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-6.047/( ( (207.666 - 38.379) + (188.707 - 39.765) )/ 2 )
=-6.047/( (169.287+148.942)/ 2 )
=-6.047/159.1145
=-3.80 %

Zhejiang Taimei Medical Technology Co's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-5.126/( ( (183.354 - 30.356) + (188.707 - 39.765) )/ 2 )
=-5.126/( ( 152.998 + 148.942 )/ 2 )
=-5.126/150.97
=-3.40 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -3.40% mean?
Zhejiang Taimei Medical Technology Co (FRA:A2V) has a ROCE % of -3.40% as of Dec. 2025.
Is Zhejiang Taimei Medical Technology Co's ROCE % too high?
Zhejiang Taimei Medical Technology Co's current ROCE % is -3.40%. Overall, Zhejiang Taimei Medical Technology Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Taimei Medical Technology Co's ROCE % compare to VEEV and BTSG?
Zhejiang Taimei Medical Technology Co's ROCE % of -3.40% can be compared against companies in the Healthcare Providers & Services industry. The industry median ROCE % is 6.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Healthcare Providers & Services company?
The median ROCE % among Healthcare Providers & Services companies is 6.46, based on 640 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median ROCE % is 6.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Taimei Medical Technology Co's current ROCE % is -3.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Taimei Medical Technology Co stock overvalued right now?
Zhejiang Taimei Medical Technology Co (FRA:A2V) has a current ROCE % of -3.40%. The current ROCE % is -3.40%. Zhejiang Taimei Medical Technology Co's overall GF Score™ is 11/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Zhejiang Taimei Medical Technology Co (FRA:A2V), the current ROCE % is -3.40% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zhejiang Taimei Medical Technology Co Business Description

Other Exchanges 02576:Hong Kong
Address 36 Changsheng South Road, 3rd Floor, Building 9, Smart Industry Innovation Park, Zhejiang Province, Jiaxing, CHN
Zhejiang Taimei Medical Technology Co Ltd is a digital solution provider focused on the pharmaceutical and medical device industry in China. It designs and delivers industry-specific software and digital services that facilitate research and development (R&D) and the commercialization of pharmaceuticals and medical devices. The software it offers is cloud-based, allowing users to access it from various devices at any time over the internet, without the need for software installation and maintenance on their devices. It has a geographical presence in Mainland China, the United States, Singapore, Korea, and Others.
11GF Score

Get the complete analysis for FRA:A2V

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.60
Price